文献速递类风湿关节炎

荷兰类风湿关节炎患者生物制剂减量策略的成本-效用分析

Cost-utility analysis of tapering strategies of biologicals in rheumatoid arthritis patients in the Netherlands.
PubMed 文献 · Ann Rheum Dis · 2023-07-09

研究从社会视角用马尔可夫模型模拟荷兰类风湿关节炎患者30年内生物制剂减量、停药及减量后停药三种策略与继续治疗的比较。结果显示三种减量策略均造成质量调整生命年损失,每损失一个QALY的增量成本-效果比分别为115157、74226和67137欧元。

要点

  • 减量、减量后停药和停药的ICER分别为每损失一个QALY 115157、74226和67137欧元。
  • 在每损失一个QALY支付意愿阈值50000欧元下,三种策略具有成本-效果的概率分别为76.1%、64.3%和60.1%。
  • 50%减量策略每损失一个QALY所节省的成本最高。

核心结论

  • 基于该分析,50%减量策略每损失一个QALY所节省的成本最高。

研究设计与样本

  • 采用社会视角的马尔可夫模型,时间跨度为30年寿命期,模拟28个关节疾病活动度(DAS28)定义的缓解(<2.6)、低疾病活动度(2.6<DAS28<3.2)和中高疾病活动度(DAS28>3.2)健康状态之间每3个月的转换。
  • 转换概率通过文献检索和随机效应合并估计。
  • 比较了50%剂量减量(减量)、停药以及50%剂量减量后停药(降阶)三种策略与继续治疗的增量成本、增量质量调整生命年(QALY)、增量成本-效果比(ICER)和增量净货币效益。
  • 进行了确定性、概率敏感性分析和多重情景分析。

主要发现

  • 30年后,减量、降阶和停药策略的ICER分别为每损失一个QALY 115157欧元、74226欧元和67137欧元,主要由生物制剂成本节省和72.8%的生活质量损失概率驱动。

关键数值与推荐

  • 在每损失一个QALY支付意愿阈值为50000欧元时,减量、降阶和停药策略具有成本-效果的概率分别为76.1%、64.3%和60.1%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Current guidelines recommend tapering biological disease-modifying antirheumatoid drugs (bDMARDs) in rheumatoid arthritis (RA) if the disease is under control. However, guidelines on tapering are lacking. Assessing cost-effectiveness of different tapering strategies might provide broader input for creating guidelines on how to taper bDMARDs in patients with RA. The aim of this study is to evaluate the long-term cost-effectiveness from a societal perspective of bDMARD tapering strategies in Dutch patients with RA, namely 50% dose reduction (tapering), discontinuation and a 50% dose reduction followed by discontinuation (de-escalation). METHODS: Using a societal perspective, a Markov model with a life-time horizon of 30 years was used to simulate 3-monthly transitions between Disease Activity 28 (DAS28)-defined health states of remission (<2.6), low disease activity (2.6<DAS28<3.2) and medium-high disease activity (DAS28>3.2). Transition probabilities were estimated through literature search and random effects pooling. Incremental costs, incremental quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs) and incremental net monetary benefits for each tapering strategy were compared with continuation. Deterministic, probabilistic sensitivity analyses and multiple scenario analyses were performed. RESULTS: After 30 years, the ICERs were €115 157/QALY lost, €74 226/QALY lost and €67 137/QALY lost for tapering, de-escalation and discontinuation, respectively; mainly driven by bDMARD cost savings and a 72.8% probability of a loss in quality of life. This corresponds to a 76.1%, 64.3% and 60.1% probability of tapering, de-escalation and discontinuation being cost-effective, provided a willingness-to-accept threshold of €50 000/QALY lost. CONCLUSIONS: Based on these analyses, the 50% tapering approach saved the highest cost per QALY lost.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. van Esveld L, Cox JM, Kuijper TM, et al. Cost-utility analysis of tapering strategies of biologicals in rheumatoid arthritis patients in the Netherlands. Ann Rheum Dis. 2023. PMID: 37423648. doi:10.1136/ard-2023-224190

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。